Siva Therapeutics Inc.
Nanotechnology-enabled photothermal therapy for skin cancer
This article was originally published in Start Up
Executive Summary
Siva Therapeutics Inc. aims to destroy skin cancer cells from within by using its SivaRods, gold nanoparticles that combine with near-infrared light to create precisely targeted hyperthermia that destroys tumors with minimal collateral damage.
You may also be interested in...
Medtech Start-Ups Innovate In Treating Advanced Skin Cancer
Nanotechnology, electroporation, and superficial radiotherapy are some of the tools device start-ups are deploying as alternatives to toxic drug regimens and surgery for treating skin cancer. We profile three emerging companies in this issue: OncoSec Medical, Sensus Healthcare, and Siva Therapeutics.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.